CA3038870C — Lidocaine formulations for use in chronic open wounds
Assigned to Trilogic Pharma LLC · Expires 2025-05-20 · 1y expired
What this patent protects
The present invention relates to topical dosages and formulations of lidocaine and pharmaceutically acceptable salts thereof, which are effective, chemically stable and physiologically balanced for safety and efficacy, particularly for debridement pain, and increase the duration …
USPTO Abstract
The present invention relates to topical dosages and formulations of lidocaine and pharmaceutically acceptable salts thereof, which are effective, chemically stable and physiologically balanced for safety and efficacy, particularly for debridement pain, and increase the duration of pain relief, and thus provide more effective treatment for chronic open wounds, especially those in non-mucous tissue.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.